Although less stable in plasma than NT-proBNP10, BNP, the other biomarker of CHF, is still widely and routinely assayed on analyzers in hospital laboratories, and thus remains of potential interest for the follow-up of cardiac function under MAD treatment. This evidence concerns the gene NPPB and congestive heart failure.